文献速递妇产影像腹部CT

高级别浆液性卵巢癌新辅助化疗:疗效评估的影像-病理相关性与进展预测因素

Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression.
PubMed 文献 · Abdom Radiol (NY) · 2024-03-13

回顾性纳入97例接受新辅助化疗的高级别浆液性卵巢癌患者,于化疗前后行腹盆腔CT并计算简化腹膜癌指数(S-PCI),术后病理评定化疗反应评分(CRS)。CT S-PCI在治疗后显著下降,但其下降幅度与CRS分级、肿瘤减灭是否理想均无显著差异;仅残余病理病变(CRS 1/2)和CA-125变化预测进展。

要点

  • CT S-PCI评分观察者间一致性良好至优秀(ICC 0.64-0.77)。
  • 化疗后CT S-PCI显著下降,但降幅与病理CRS分级无关。
  • 仅残余病理病变CRS 1/2和CA-125变化预测进展。

核心结论

  • 高级别浆液性卵巢癌对新辅助化疗的CT S-PCI反应不能预测病理CRS评分、理想减灭或进展,提示影像、病理、生化及手术评估之间存在不一致。

研究设计与样本

  • 回顾性、符合HIPAA、经IRB批准的研究,2010至2019年间396例接受新辅助化疗的HGSC女性中排除299例后纳入97例,中位年龄65岁±10;化疗前后腹盆腔CT评定S-PCI 0-24分,手术标本评定CRS 1-3分,并行单因素、多因素及生存分析。

诊断标准与关键数值

  • CT S-PCI评分0-24分(分值越高肿瘤负荷越大),观察者间ICC 0.64-0.77;病理CRS 1-3分(1分为 minimal response 至3分为完全反应);联合Cox比例风险模型显示残余病理病变CRS 1/2预测进展HR 4.19(p<0.001),CA-125变化预测进展HR 1.79(p=0.01)。

临床应用与阅片要点

  • 阅片时可按S-PCI 0-24分评估腹膜肿瘤负荷并记录化疗前后变化;但CT S-PCI降幅与病理CRS分级、肿瘤减灭理想与否均无显著相关,报告影像反应时需注意其与病理及生化评估可能不一致。

局限性

  • 原文为回顾性研究。
  • 396例中299例因未手术或影像/病理不可用而被排除。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Neoadjuvant chemotherapy is often administered for high-grade serous ovarian carcinoma (HGSC) prior to cytoreductive surgery. We evaluated treatment response by CT (simplified peritoneal carcinomatosis index [S-PCI]), pathology (chemotherapy response score [CRS]), laboratory markers (serum CA-125), and surgical outcomes, to identify predictors of disease-free survival.

METHODS: For this retrospective, HIPAA-compliant, IRB-approved study, we identified 396 women with HGSC receiving neoadjuvant chemotherapy between 2010 and 2019. Two hundred and ninety-nine patients were excluded (surgery not performed; imaging/pathology unavailable). Pre- and post-treatment abdominopelvic CTs were assigned CT S-PCI scores 0-24 (higher score indicating more tumor). Specimens were assigned CRS of 1-3 (minimal to complete response). Clinical data were obtained via chart review. Univariate, multivariate, and survival analyses were performed.

RESULTS: Ninety-seven women were studied, with mean age of 65 years ± 10. Interreader agreement was good to excellent for CT S-PCI scores (ICC 0.64-0.77). Despite a significant decrease in CT S-PCI scores after treatment (p < 0.001), mean decrease in CT S-PCI did not differ significantly among CRS categories (p = 0.20) or between patients who were optimally versus suboptimally debulked (p = 0.29). In a survival analysis, lower CRS (more viable tumor) was associated with shorter time to progression (p < 0.001). A joint Cox proportional-hazard models showed that only residual pathologic disease (CRS 1/2) (HR 4.19; p < 0.001) and change in CA-125 (HR 1.79; p = 0.01) predicted progression.

CONCLUSION: HGSC response to neoadjuvant therapy by CT S-PCI did not predict pathologic CRS score, optimal debulking, or progression, revealing discordance between imaging, pathologic, biochemical, and surgical assessments of tumor response.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Roseland ME, Ma T, Shampain KL, et al. Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression. Abdom Radiol (NY). 2024. PMID: 38478037. doi:10.1007/s00261-024-04215-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。